Key Takeaways
- • William Blair has acquired Armentum Partners, a boutique debt and alternative capital advisory firm, marking the firm's second investment banking acquisition of 2026.
- • Armentum brings debt advisory, enterprise value lending, asset-based lending, and royalty monetization capabilities, focused primarily on healthcare and technology companies.
- • Armentum has raised more than $22 billion across more than 390 transactions since its founding, and its senior team has over 200 years of combined experience.
- • All Armentum professionals are expected to join William Blair, which will open a Menlo Park office to establish a direct Silicon Valley presence.
- • William Blair said the deal responds to rising demand for private credit and non-dilutive financing among venture-backed and public companies.
Summary
William Blair has acquired Armentum Partners, a boutique debt and alternative capital advisory firm serving venture-backed companies, public companies, academic institutions, and other organizations. According to the announcement, the transaction is William Blair's second investment banking acquisition of 2026 and broadens the firm's capabilities across debt advisory, enterprise value lending, asset-based lending, and royalty monetization.
Armentum focuses primarily on the healthcare and technology sectors, advising high-growth companies on customized financing strategies. Its client base includes venture capital investors, public companies, growth-oriented lenders, and enterprise-value lenders. Its royalty monetization practice advises academic institutions and life sciences companies seeking to generate capital from intellectual property and royalty streams. Since its founding, Armentum has raised more than $22 billion across more than 390 transactions, and its senior banking team has more than 200 years of combined experience spanning investment banking, commercial banking, lending, venture financing, and private and public equity investing. The firm has professionals in Boston, Chicago, Menlo Park, New York, Philadelphia, and San Francisco, and serves clients across the United States and Europe.
All Armentum professionals are expected to join William Blair, which will also open an office in Menlo Park. Armentum will continue operating under its existing name for a period following the transaction. Clearsight Advisors served as financial advisor to Armentum Partners on the deal.
William Blair said the acquisition responds to increasing demand for private credit and other non-dilutive financing among venture-backed and public companies, with particularly strong growth in healthcare innovation, artificial intelligence, software, consumer, media, fintech, and industrial technology. The firm also sees rising demand from later-stage technology and biopharmaceutical companies seeking financing for clinical development, commercialization, and acquisitions. The deal follows William Blair's recent life sciences expansion, including the hires of Michael Allwin as Head of Biopharma Investment Banking, Emanuela Branchetti as Managing Director of Scientific Affairs, and Alethia Young in equity research. The firm's investment banking group advised on more than $880 billion in completed transaction volume from July 2021 through June 2026.
Matt Zimmer, Global Head of Investment Banking at William Blair, said the firm continues to invest in capabilities serving venture capital, public company, and collegiate clients. Steve Maletzky, Head of Capital Markets, described enterprise value lending as a specialized discipline and called the deal a natural extension of the firm's capital markets strategy. Hutch Corbett of Armentum said joining William Blair adds scale, reach, and sector depth, allowing the firm to offer public and private equity capital raising, M&A advisory, secondary advisory, primary fundraising, and equity research.
Armentum focuses primarily on the healthcare and technology sectors, advising high-growth companies on customized financing strategies. Its client base includes venture capital investors, public companies, growth-oriented lenders, and enterprise-value lenders. Its royalty monetization practice advises academic institutions and life sciences companies seeking to generate capital from intellectual property and royalty streams. Since its founding, Armentum has raised more than $22 billion across more than 390 transactions, and its senior banking team has more than 200 years of combined experience spanning investment banking, commercial banking, lending, venture financing, and private and public equity investing. The firm has professionals in Boston, Chicago, Menlo Park, New York, Philadelphia, and San Francisco, and serves clients across the United States and Europe.
All Armentum professionals are expected to join William Blair, which will also open an office in Menlo Park. Armentum will continue operating under its existing name for a period following the transaction. Clearsight Advisors served as financial advisor to Armentum Partners on the deal.
William Blair said the acquisition responds to increasing demand for private credit and other non-dilutive financing among venture-backed and public companies, with particularly strong growth in healthcare innovation, artificial intelligence, software, consumer, media, fintech, and industrial technology. The firm also sees rising demand from later-stage technology and biopharmaceutical companies seeking financing for clinical development, commercialization, and acquisitions. The deal follows William Blair's recent life sciences expansion, including the hires of Michael Allwin as Head of Biopharma Investment Banking, Emanuela Branchetti as Managing Director of Scientific Affairs, and Alethia Young in equity research. The firm's investment banking group advised on more than $880 billion in completed transaction volume from July 2021 through June 2026.
Matt Zimmer, Global Head of Investment Banking at William Blair, said the firm continues to invest in capabilities serving venture capital, public company, and collegiate clients. Steve Maletzky, Head of Capital Markets, described enterprise value lending as a specialized discipline and called the deal a natural extension of the firm's capital markets strategy. Hutch Corbett of Armentum said joining William Blair adds scale, reach, and sector depth, allowing the firm to offer public and private equity capital raising, M&A advisory, secondary advisory, primary fundraising, and equity research.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.